Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial
Somatostatin may inhibit pancreatic secretion and has been tested for PEP prophylaxis. No perforation or death occurred during the study. The aim of the current study was to investigate whether somatostatins were more important than the rest.
